PBLA — Panbela Therapeutics Cashflow Statement
0.000.00%
- $1.17m
- $7.42m
Annual cashflow statement for Panbela Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -6.2 | -4.77 | -10.1 | -34.9 | -25.3 |
Non-Cash Items | 3.27 | 1.1 | 1.29 | 19.1 | 0.661 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.187 | -0.205 | 1.6 | 0.555 | -0.647 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -2.74 | -3.87 | -7.25 | -15.3 | -25.2 |
Other Investing Cash Flow Items | — | — | 0 | -0.656 | 0.4 |
Sale of Business | |||||
Purchase of Investments | |||||
Change in Net Intangibles | |||||
Cash from Investing Activities | — | — | 0 | -0.656 | 0.4 |
Financing Cash Flow Items | — | — | — | — | -0.01 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 3.78 | 10.4 | 10.1 | 5.35 | 26.1 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 1.04 | 6.57 | 2.85 | -10.6 | 1.29 |